Table 1.
Efficiency of PSN relative to EL
| Relative Efficiencya | |||||||
|---|---|---|---|---|---|---|---|
| γV | γP | β0 | β1 | β2 | β3 | VE{S(1)} | VENew(Δ) |
| 1 | 0 | 1.05 | 1.08 | 1.05 | 1.07 | 1.08 | 1.06 |
| 1 | 1 | 1.03 | 1.17 | 1.04 | 1.18 | 1.36 | 1.22 |
| 5 | 0 | 1.00 | 1.00 | 1.00 | 1.00 | 0.99 | 0.99 |
| 5 | 5 | 1.03 | 1.07 | 1.04 | 1.08 | 1.08 | 1.08 |
| 10 | 0 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| 10 | 10 | 1.07 | 1.07 | 1.08 | 1.07 | 1.07 | 1.08 |
| 16.62b | 0 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| 16.62b | 15.5c | 1.07 | 1.05 | 1.08 | 1.05 | 1.04 | 1.06 |
| 1 | 2 | 1.06 | 1.30 | 1.08 | 1.32 | 1.72 | 1.43 |
| 2 | 5 | 1.15 | 1.32 | 1.18 | 1.32 | 1.44 | 1.40 |
| 1 | 10 | 2.23 | 2.75 | 2.33 | 2.76 | 10.73 | 3.87 |
| 5 | 10 | 1.17 | 1.22 | 1.19 | 1.22 | 1.24 | 1.26 |
a
efficiency of PSN relative to EL = var(EL)/var(PSN)
b
γV = 16.62 corresponds to sampling all uninfected vaccinees
c
γP = 15.5 corresponds to sampling all uninfected placebo recipients